And unfortunately, you know, different drugs have different adverse effects, different risks, which is why you're always hearing physicians talk about risk benefit analysis
We are always very transparent about the pharmacies that we use, and we have good relationships with our pharmacies
5% AHK-Cu (Copper Tripeptide-3): Specifically prized in hair research for its ability to target the hair follicles and support the growth phase (Anagen)
Industry publications framed the event in stark terms, with one headline reading, Skye Bioscience stock plummets after failed weight loss drug trial. SEC Filings & Risk Factors Skye's 2024 10-K (March 20, 2025) disclosed standard biotech perils: "Clinical trials may fail to demonstrate safety and efficacy," with specifics on nimacimab's Phase 2 uncertainties, including "potential for suboptimal dosing" and "failure to meet endpoints." Yet plaintiffs argue these were boilerplate, omitting known gaps in preclinical-to-clinical translation